ZA200808017B - Tetrahydropyridothienopyrimidine compounds and methods of use thereof - Google Patents

Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Info

Publication number
ZA200808017B
ZA200808017B ZA200808017A ZA200808017A ZA200808017B ZA 200808017 B ZA200808017 B ZA 200808017B ZA 200808017 A ZA200808017 A ZA 200808017A ZA 200808017 A ZA200808017 A ZA 200808017A ZA 200808017 B ZA200808017 B ZA 200808017B
Authority
ZA
South Africa
Prior art keywords
tetrahydropyridothienopyrimidine
compounds
methods
tetrahydropyridothienopyrimidine compounds
Prior art date
Application number
ZA200808017A
Other languages
English (en)
Inventor
Zhang Chengzhi
Sidhu Kanwar
Lobell Mario
Ladouceur Gaetan
Zhao Qian
Liu Zheng
Kristen M Allegue
Chetan P Darne
Newcom Jason
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200808017B publication Critical patent/ZA200808017B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
ZA200808017A 2006-03-20 2008-09-18 Tetrahydropyridothienopyrimidine compounds and methods of use thereof ZA200808017B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78414606P 2006-03-20 2006-03-20

Publications (1)

Publication Number Publication Date
ZA200808017B true ZA200808017B (en) 2009-11-25

Family

ID=38523058

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808017A ZA200808017B (en) 2006-03-20 2008-09-18 Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Country Status (29)

Country Link
US (1) US8501755B2 (xx)
EP (1) EP2001890B1 (xx)
JP (1) JP5282026B2 (xx)
KR (1) KR20080110834A (xx)
CN (1) CN101448840B (xx)
AR (1) AR059901A1 (xx)
AT (1) ATE495179T1 (xx)
AU (1) AU2007227317A1 (xx)
BR (1) BRPI0711045A2 (xx)
CA (1) CA2647036C (xx)
CR (1) CR10304A (xx)
DE (1) DE602007011906D1 (xx)
DO (1) DOP2007000053A (xx)
EC (1) ECSP088749A (xx)
ES (1) ES2357654T3 (xx)
GT (1) GT200800187A (xx)
IL (1) IL194028A0 (xx)
MA (1) MA30351B1 (xx)
MX (1) MX2008012006A (xx)
NZ (1) NZ571326A (xx)
PA (1) PA8719401A1 (xx)
PE (1) PE20080144A1 (xx)
RU (1) RU2008141239A (xx)
SV (1) SV2008003032A (xx)
TN (1) TNSN08370A1 (xx)
TW (1) TW200804397A (xx)
UY (1) UY30220A1 (xx)
WO (1) WO2007109279A2 (xx)
ZA (1) ZA200808017B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
EP2212332B1 (en) * 2007-09-14 2012-10-24 Bayer Intellectual Property GmbH Substituted tricyclic compounds and methods of use thereof
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
WO2013112699A2 (en) * 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US20170107229A1 (en) * 2014-05-26 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted tetrahydropyridothienopyrimidines
US10561749B2 (en) 2015-07-03 2020-02-18 Kyoto University Nuclear medicine diagnostic imaging agent
DK3474846T3 (da) 2016-06-22 2023-02-06 Univ Vanderbilt Positive, allosteriske modulatorer af den muskarinske acetylcholinreceptor m4
MA47126A (fr) 2016-11-07 2019-10-30 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
BR112018013882A2 (pt) 2016-11-07 2018-12-18 Vanderbilt University moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
WO2018085813A1 (en) 2016-11-07 2018-05-11 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN111406058A (zh) 2017-12-05 2020-07-10 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
US20220177488A1 (en) * 2019-03-19 2022-06-09 Suvalent Therapeutics, Inc. Sumo inhibitor compounds and uses thereof
WO2023015240A1 (en) * 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Tricyclic fused pyrimidine compounds for use as her2 inhibitors
CN114736154B (zh) * 2022-03-15 2023-07-21 安庆朗坤药业有限公司 N-(3-氯-4-(2-吡啶甲氧基)苯基)-2-氰基乙酰胺的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323719A1 (en) * 1999-03-30 2003-07-02 Nippon Soda Co., Ltd. Thienopyrimidine compounds and salts thereof and process for the preparation of the same
DE19944604A1 (de) * 1999-09-17 2001-03-22 Merck Patent Gmbh Aminderivate
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2003035653A1 (fr) * 2001-10-26 2003-05-01 Nippon Soda Co.,Ltd. Compose pyridothienopyrimidine et son sel
WO2005010008A1 (en) * 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders

Also Published As

Publication number Publication date
ES2357654T3 (es) 2011-04-28
IL194028A0 (en) 2009-09-22
DE602007011906D1 (de) 2011-02-24
EP2001890A2 (en) 2008-12-17
AR059901A1 (es) 2008-05-07
JP5282026B2 (ja) 2013-09-04
JP2009530387A (ja) 2009-08-27
CN101448840B (zh) 2011-12-14
DOP2007000053A (es) 2007-09-30
MX2008012006A (es) 2008-10-03
CA2647036C (en) 2015-06-23
CN101448840A (zh) 2009-06-03
SV2008003032A (es) 2009-11-26
ECSP088749A (es) 2008-10-31
WO2007109279A2 (en) 2007-09-27
CR10304A (es) 2009-01-27
CA2647036A1 (en) 2007-09-27
TW200804397A (en) 2008-01-16
BRPI0711045A2 (pt) 2012-06-26
MA30351B1 (fr) 2009-04-01
EP2001890B1 (en) 2011-01-12
RU2008141239A (ru) 2010-04-27
ATE495179T1 (de) 2011-01-15
PE20080144A1 (es) 2008-04-06
US20100298297A1 (en) 2010-11-25
TNSN08370A1 (en) 2009-12-29
WO2007109279A3 (en) 2007-12-21
UY30220A1 (es) 2007-10-31
PA8719401A1 (es) 2009-02-09
NZ571326A (en) 2011-07-29
AU2007227317A1 (en) 2007-09-27
KR20080110834A (ko) 2008-12-19
GT200800187A (es) 2009-04-07
US8501755B2 (en) 2013-08-06

Similar Documents

Publication Publication Date Title
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
EP2094085A4 (en) ANTI-CHOLESTEROLMIC COMPOUNDS AND METHODS OF USE
GB0718972D0 (en) Compounds and methods of making the compounds
HK1135099A1 (en) Aza-indolyl compounds and methods of use
IL193693A0 (en) Purine compounds and methods of use thereof
EP2021555A4 (en) STRUCTURAL ELEMENT AND METHODS OF USE THEREOF
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
IL206125A0 (en) Azaindolizines and methods of use
GB0611115D0 (en) Compounds and their use
IL192564A0 (en) Composition and method of use thereof
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
ZA201004894B (en) Nuctraceutical composition and methods of use
IL192820A0 (en) Novel compounds and use thereof
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
ZA201004893B (en) Nuctraceutical composition and methods of use
IL192552A0 (en) Dnt-succinate and methods of preparation thereof
ZA200807956B (en) Purine compounds and methods of use thereof
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use
AU2006907075A0 (en) Compounds and Methods of Use